Clinical trials, regulatory work, functional ingredients and AI — one company

A message from our co-CEOs

AriBnC was founded in Yongin, Gyeonggi-do, on 1 September 2021. We started out designing nonclinical studies and running human application studies for clients’ individually recognised health functional food ingredients, and handling clinical-trial statistics on their behalf. Doing this contract work, we learned that clinical studies alone are not enough to win government recognition or approval for a health functional food, a medical device or a similar product. However good the data, it is of little use unless it is prepared as the documents and dossiers each country’s rules require; and however well the regulatory (RA) documents are put together, they will not be accepted without sufficient scientific evidence behind them.

So we widened our scope. Today one team carries the work through from start to finish — from nonclinical and toxicology studies in cells and animals, to human application studies and clinical trials in people, to the submission dossiers for Korea’s MFDS, the US FDA, Health Canada and the European Union (EU). Biostatistical analysis and EDC build and operation are done in-house at our Yongin laboratory rather than outsourced, so no information is lost or dropped as a project moves from one stage to the next. We currently work under contract with companies in the United States, Italy, India, China, Vietnam and other countries across a range of fields.

More recently we began researching and developing AI models from the data our own research has built up, and accordingly, since 2026 the ‘BnC’ in our company name has stood for ‘Bio & Computing’. The name has not changed — what it covers has grown wider. Whatever AriBnC takes on, two principles stay the same.

First, we build accurate and sufficient scientific evidence so that regulators can judge correctly.

Second, our clients’ goals are our goals, and our clients’ success is our success.

Co-CEOs Yunsuk Chun · Jongkyu Kim